A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

NCT01067521 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1404

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG: Glatiramer acetate (GA)
DRUG: Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.